The status and progress of neoadjuvant therapy for boardline resectable pancreatic cancer / 中华肝胆外科杂志

ABSTRACT

The proportion of boardline resectable pancreatic cancer (BRPC) is relatively high in patients with pancreatic cancer. At present, the main therapeutic treatment of BRPC is surgical resection after neoadjuvant therapy. Therefore, the neoadjuvant therapy of BRPC has drawn more and more attention in recent years. Once making a breakthroug in the treatment plan, it can greatly improve the overall prognosis of patients with pancreatic cancer. In this study, the development process, specific programs, advantages and disadvantages of each plan and the current research progress of BRPC neoadjuvant therapy are discussed.